EditorsAbout the SiteComes vs. MicrosoftUsing This Web SiteSite ArchivesCredibility IndexOOXMLOpenDocumentPatentsNovellNews DigestSite NewsRSS

09.09.18

The Battle Over PTAB Determines the Fate of Patent Quality in the United States

Posted in America, Patents at 12:56 pm by Dr. Roy Schestowitz

Summary: Patent Trial and Appeal Board (PTAB) inter partes reviews (IPRs) are under attack by Iancu, a longtime proponent of software patents who would not mind letting patent quality slip even further to help the litigation ‘industry’

THE NEED to limit the scope of patents is well understood among examiners at the EPO (albeit not the management). The appeal boards exist there for a reason, but they cannot quite function anymore because they lost their independence. António Campinos can exercise authority and power over them. Battistelli abused them aplenty. This is what happens when the leadership of the Office threatens and limits the actions of actual judges.

In the US, the Patent Trial and Appeal Board (PTAB) serves a similar function. It can undo mistakes made by examiners by handling inter partes reviews (IPRs), in effect voiding US patents (that already got granted). PTAB is sometimes saving lives (almost literally) by battling unjust patent monopolies which do not advance science but actively prevent or impede scientific progress while killing those in need of it. As IP Watch put it a few days ago (in relation to PTAB although much of the same can be said about Europe):

A newly released study shows that generic drug companies win nearly half the time when challenging patents on United States government-approved pharmaceutical products through the Patent Trial and Appeal Board (PTAB) process.

[...]

PORTAL’s new study demonstrates that generic drug manufacturers have embraced the new process, challenging 198 patents covering 134 different drug products over the last 5 years. In 43% of the inter partes review cases since 2011, the challengers succeeded in overturning all challenged patent claims. In addition, inter partes review for drug patents has consistently been completed within 12 months, as required by statute—much faster than litigation. According to Dr. Darrow, “In the pharmaceutical market, the inter partes review process can meaningfully contribute to competition and lower drug prices by ensuring that invalid patents do not block timely availability of generic drugs and by resolving many patent disputes in a more efficient manner than was previously possible.”

Not too long ago we wrote about how a firm called Asha Nutrition dealt with the EPO's appeal boards. It has just been ‘intercepted’ by PTAB (tackling the same firm in Bhagat v Iancu) using Section 101 and more. As Dennis Crouch put it just before the weekend:

Bhagat v. Iancu is a newly filed petition for writ of certiorari now pending before the United States Supreme Court. (Case No. 18-277). Bhagat is the founder and CEO of Asha Nutrition and is seeking to patent a lipid-formulation – that contains a mixture of omega-6 and omega-3 faty acids at a ratio of 4:1 or greater.

The USPTO refused to issue the patent finding the claims barred both by on eligibility (101) and anticipation (102) grounds. On appeal, the Federal Circuit affirmed. The 101 denial is most interesting. The PTAB found that that claimed fatty-acid mixtures already occur naturally in walnut oil and olive oil. And, although the claims require (via disclaimer) that the mixture of oils come from different sources, the Board found them to be directed to a natural phenomenon. On appeal, the Federal Circuit agreed — finding that the original ingredients of walnut oil and olive oil are natural products and the mixtures were not shown to be a “transformation of the natural products, or that the claimed mixtures have properties not possessed by these products in nature.”

So now even the Federal Circuit is affirming, as usual. Patents in the biotechnology/chemical/pharmaceutical (BCP) domain have just been promoted by a site that advocates patents on life/nature; there are many reasons to reject such patents, especially in light of some particular SCOTUS rulings, which the USPTO begrudgingly follows.

Crouch has also written about IPRs, in particular a case about patents from which a question arose: who can petition? Who can file IPRs?

The appeal here stems from three Inter Partes Review (IPR) proceedings — each cancelling the claims of aseparate Worlds’ patent. U.S. Patent Nos. 7,945,856; 8,082,501; and 8,145,998. The Worlds’ patents involve methods and systems for displaying avatars within a virtual environment and claim priority back to a 1995 provisional patent application.

The appeal here does not focus on the merits of the case but rather whether the IPR proceedings were time barred. I.e., whether the patentee’s still-pending lawsuit against Bungie’s contracting partner Activision will block Bungie from pursuing its IPR.

[...]

In the IPR, the patentee Worlds requested discovery on the connection between Bungie and Activision in order to determine whether Activision could be considered a “real party in interest” or “privy.” However, that request was summarily denied and the PTAB concluded that the patentee “has not demonstrated that Activision is an unnamed real party in interest in this proceeding.”

On appeal, the Federal Circuit has vacated and remanded — holding that the PTAB should have investigated the relationship between the IPR petitioner (Bungie) and the prior litigant (Activision) and that the PTAB should have explained its reasoning.

[...]

On remand, the Board will reconsider its the real-party-in-interest decision — placing the ultimate burden of persuasion on the IPR petitioner.

The Federal Circuit did not overrule this judgment; instead it just adds another dimension to it, having recently done that to RPX (and by extension parties like Unified Patents as well).

There’s a coordinated effort to undermine PTAB, but it has not really worked, at least not yet. PTAB is only getting more prolific over time.

Watchtroll (Gene Quinn) now promotes Kavanaugh as part of his ‘crusade’ against patent quality, e.g. PTAB and more. This blowhard lawyer/attorney makes the patent ‘industry’ (profession) look like a bunch of Republicans; here he goes saying:

As was the case with Justice Neil Gorsuch, Kavanaugh has a history of being skeptical toward the growth of the Administrative State, which means the growth of agency power is not something he has shown a predisposition to being in favor of in his decisions. Given the outsized importance of the Patent Trial and Appeal Board (PTAB) within the patent industry, and the fact that the Supreme Court has already twice mentioned “shenanigans” in PTAB procedures…

What “shenanigans”? The ones Watchtroll makes up? The ones that Koch-funded anti-PTAB groups try to bring up, only to be echoed by Gorsuch? That actually happened.

HTIA responds to the observation that the current leadership at the USPTO is PTAB-hostile and under attack by Iancu. “Today’s patent system is the product of nearly a decade of reform,” HTIA said a few days ago, “thanks to which the quality of U.S.-issued patents has gone up and American innovation is flowering.” They link to an older article from John Thorne.

On the other hand we have patent maximalists, not technology companies. “USPTO begins process for finding new leadership at the PTAB,” Watchtroll wrote, after they had smeared the chief judge (he has been moved or voluntarily moved elsewhere last month). Iancu has been condemned for this kind of attitude since (CCIA and EFF spoke out) and here he is in his own words:

Andrei Iancu: Chief Judge Ruschke, he hasn’t left the PTO, obviously. He will be in a new role at the PTO addressing an important issue for the office, which is the coordination between the PTAB and the overall patents organization. Sometimes there is a gap between the two organizations that we would like to bridge, or at least minimize. He will take on that role and study that issue and try to make suggestions on how to improve it. I do think it’s an important function to address. And at the PTAB, we will have new leadership. For now, come September 2nd, the acting chief will be Scott Boalick, and the acting deputy chief will be Jackie Bonilla.

IPO and the EPO are getting together to promote software patents quite soon. Patent maximalists who have just advertised this event say that “[i]n addition, Andrei Iancu, Under Secretary of Commerce for Intellectual Property and Director of the U.S. Patent and Trademark Office will present a keynote address on September 24, and Hon. Kathleen O’Malley, Circuit Judge, U.S. Court of Appeals for the Federal Circuit will present a keynote address on September 25.”

That’s a fortnight from now.

IPO has also just advertised this PTAB event whose panel/debate is stuffed with patent maximalists:

The Intellectual Property Owners Association (IPO) will offer a one-hour webinar entitled “The Revised PTAB Trial Practice Guide and Its Impact on Your Practice” on September 13, 2018 from 2:00 to 3:00 pm (ET). Hon. Michael Tierney, Lead Administrative Patent Judge, Patent Trial and Appeal Board, U.S. Patent and Trademark Office; Tarek Fahmi of Ascenda Law Group; and Eliot Williams of Baker Botts LLP will discuss the reasoning behind recent changes to the PTAB Trial Practice Guide and explain how these revisions will impact PTAB practice.

The management of the USPTO keeps trying to weaken PTAB, but courts aren’t letting that happen. It’s going to be interesting to see if Iancu can maintain the fiction that he’s impartial. Seeing the like of Watchtroll in person has been quite a giveaway. He did the same with IAM. Whose Director is he? His private firm’s?

Share this post: These icons link to social bookmarking sites where readers can share and discover new web pages.
  • Digg
  • del.icio.us
  • Reddit
  • co.mments
  • DZone
  • email
  • Google Bookmarks
  • LinkedIn
  • NewsVine
  • Print
  • Technorati
  • TwitThis
  • Facebook

If you liked this post, consider subscribing to the RSS feed or join us now at the IRC channels.

Pages that cross-reference this one

2 Comments

  1. Asha Admin said,

    September 15, 2018 at 4:23 pm

    Gravatar

    Dennis Crouch’s article on Bhagat v. Iancu dated September 6, 2018, has many discrepancies. For example, paragraph one misleads the reader into thinking Bhagat “is seeking to patent a lipid-formulation – that contains a mixture of omega-6 and omega-3 faty acids at a ratio of 4:1 or greater.” However, the actual claims is,

    65. A lipid-containing formulation, comprising a dosage of omega-6 and omega-3 fatty acids at an omega-6 to omega-3 ratio of 4: 1 or greater, contained in one or more complementing casings providing controlled delivery of the formulation to a subject, wherein at least one casing comprises an intermixture of lipids from different sources, and wherein (1) omega-6 fatty acids are 4-75% by weight of total lipids and omega-3 fatty acids are 0.1-30% by weight of total lipids; or (2) omega-6 fatty acids are not more than 40 grams.

    Better and fair publications on this case are available. See following:

    Where is the line between patentable subject matter and non-patentable products of nature?
    http://www.ipwatchdog.com/2018/09/07/patentable-subject-matter-non-patentable-products-of-nature/id=101134/

    “Bhagat v. Iancu – Did the Myriad Decision Overrule Funk Bros.?” by Warren Woessner
    http://www.patents4life.com/2018/09/bhagat-v-iancu-myriad-decision-overrule-funk-bros/

    “In re Urvashi Bhagat – The Slippery Slope of Natural Product Claims” by Warren Woessner
    http://www.patents4life.com/2018/03/re-urvashi-bhagat-slippery-slope-natural-product-claims/

  2. Asha Admin said,

    September 16, 2018 at 5:24 pm

    Gravatar

    There are some miscommunications in Dr. Roy Schestowitz’s article above dated September 9, 2018.

    NUMBER ONE:

    We pointed out above in our comment dated September 15, 2018, that Dr. Roy Schestowitz repeated some of the discrepancies from Dennis Crouch’s article word for word. For example, the Bhagat patent does not just claim, “a mixture of omega-6 and omega-3 faty acids at a ratio of 4:1 or greater.”

    There are numerous additional limitations in Bhagat’s claims. For example, one of the independent claims, Claim 65 recites,

    “65. A lipid-containing formulation, comprising a dosage of omega-6 and omega-3 fatty acids at an omega-6 to omega-3 ratio of 4: 1 or greater, contained in one or more complementing casings providing controlled delivery of the formulation to a subject, wherein at least one casing comprises an intermixture of lipids from different sources, and wherein (1) omega-6 fatty acids are 4-75% by weight of total lipids and omega-3 fatty acids are 0.1-30% by weight of total lipids; or (2) omega-6 fatty acids are not more than 40 grams.”

    There are over 30 claims in the Bhagat patent that were also mutilated by USPTO and alleged as patent ineligible.

    NUMBER TWO:

    Dr. Schestowitz’s “It [Bhagat patent] has just been ‘intercepted’ by PTAB.” This is also incorrect. Bhagat patent was alleged as patent ineligible by PTAB in April 2016. Bhagat appealed to US Court of Appeals for the Federal Circuit (CAFC) in August 2016, and CAFC reaffirmed without proper review in March 2018. See Open letter to USPTO and CAFC. http://asha-nutrition.com/wp-content/uploads/2018/04/Open-letter-to-USPTO-CAFC.pdf. The Petition For A Writ Of Certiorari with Supreme Court of United States was filed on September 29, 2018. See http://asha-nutrition.com/wp-content/uploads/2018/09/180829-US2009-Cert-Petition-.pdf

    EPO and USPTO have been copying each other in impropriety. Hearing before EPO Appeal Board took place in July 2017. The EPO improprieties were reported on this cite in March 2018. See http://techrights.org/2018/03/07/guest-post-epo-defrauds-small-patent-applicant-company-asha-nutrition-sciences-in-collusion-with-applicants-own-lawyer/

    NUMBER THREE – AND MOST IMPORTANT PART OF THIS COMMENT

    Dr. Roy Schestowitz states, “PTAB is sometimes saving lives (almost literally) by battling unjust patent monopolies which do not advance science but actively prevent or impede scientific progress while killing those in need of it.” This is the million dollar question, “Which patents save lives, and which patents impede scientific progress?”

    The US Supreme Court has held that Congress has provided a patent system to “have a positive effect on society through the introduction of new products and processes of manufacture into the economy, and the emanations by way of increased employment and better lives for our citizens.” Chakrabarty, 447 U.S. at 307 (quoting Kewanee Oil Co. v. Bicron Corp., 416 U.S. 470, 480 (1974)).

    The US Supreme Court has also held that the scope of patentability must be limited to avoid the “considerable danger that the grant of patents would ‘tie up’ the use of” “basic tools of scientific and technological work” and thereby ‘inhibit future innovation premised upon them.’” Myriad, 569 U.S. at 589. The formulations of the present claims do not pose a danger of such tying up.

    So there are two principles to be balanced, (1) patents must better lives for our citizens, and (2) they must not tie up basic tools.

    Bhagat claims neither preclude basic research on, or use of, any of the individual components of the claimed formulations, nor would they preclude anyone from making, using, selling, offering for sale, or importing any oil. Thus, the reasons to exclude basic tools from patent eligibility do not apply to the present claims.

    Bhagat patent is directed to solving a critical public health problem. Inventor realized confusion around lipids is a massive public health hazard continuing for centuries, and wanted to remove the problem once and for all.

    Lipids were considered important for health 6000 years ago when oils were invented, but since then lipid delivery fundamental to health has not materially advanced. Periodically, certain fatty acids (e.g., omega-3) or oils or low-fat teachings have been hailed, only to reverse a few years later. To date random oils are randomly added to foods; no guidance is given that different batches of the oils can have significantly different lipid composition and that minor lipids components present in oils can be potent. Oil making has advanced but delivery of oil for ingestion by subjects is still archaic.

    This problem is there partly because of refusal to nurture innovation via proper patent grant. Severely restricted nutrition patents are ineffective and create more confusion and chaos. These mini-patents give rise to millions of products, conflicting marketing, and competition smearing each other with “our formulation is the best and everybody else is making snake oil.” Consequently, clear teaching is lost and public stops believing everything.

    The scale of the problem is very large. According to WHO statistics, 33% of Europeans above the age of 15 have a chronic disease (e.g., heart disease, diabetes, cancer, asthma, ADHD), a large part of which is associated with mismanaged lipid consumption including omega-6 and omega-3. Premature deaths of 550,000 working age people across European Union countries from chronic diseases cost EU economies EUR 115 billion or 0.8% of GDP annually. This figure does not include the additional loss in terms of lower employment rates and productivity of people living with chronic health problems. (See http://www.oecd.org/health/europe-paying-a-heavy-price-for-chronic-diseases-finds-new-oecd-ec-report.htm).

    Furthermore, even after the disclosure of Bhagat Application, although a skilled person can practice the solutions based on the disclosure of the application, but there is little chance that public by and large can practice the solutions because less than 1% of public can understand (even name) or measure lipids in lipid sources and the problem pertains to daily life. Therefore, the solutions have to be implemented at public level, rather than skilled person level. From public health perspective, solutions have to be pre-formulated for them and they have to be taught how to adapt the solutions in daily life, a very challenging and expensive feat.

    The above backdrop lead the Inventor and the Applicant to pursue the subject patent application because in order to effectively solve the problem significant clear public teaching—overcoming the noise in the art—is required, which requires capital and a protected environment to nurture the solutions.

    The innovation would also set humanity on a course for long-term solution to several downstream problems. Not granting appealed claims is tantamount to taking the position public should be kept confused, ill, and on drugs, and this 1000s of years old problem should continue into perpetuity. Ultimate purpose of research is to enhance human condition. If the solutions devised cannot be fully applied for public benefit then the patent policy is obstructing the very purpose of research.

What Else is New


  1. Links 22/4/2019: Linux 5.1 RC6, New Release of Netrunner and End of Scientific Linux

    Links for the day



  2. USPTO and EPO Both Slammed for Abandoning Patent Quality and Violating the Law/Caselaw in Order to Grant Illegitimate Patents on Life/Nature and Mathematics

    Mr. Iancu, the ‘American Battistelli’ (appointed owing to nepotism), mirrors the ‘Battistelli operandi’, which boils down to treating judges like they’re stooges and justices like an ignorable nuisance — all this in the name of litigation profits, which necessitate constant wars over illegitimate patents (it is expensive to prove their illegitimacy)



  3. IRC Proceedings: January 27th, 2019 – March 24th, 2019

    Many IRC logs



  4. IRC Proceedings: December 2nd, 2018 – January 26th, 2019

    Many IRC logs



  5. Links 21/4/2019: SuperTuxKart's 1.0 Release, Sam Hartman Is Debian’s Newest Project Leader (DPL)

    Links for the day



  6. The EPO's Use of Phrases Like “High-Quality Patent Services” Means They Know High-Quality European Patents Are 'Bygones'

    The EPO does a really poor job hiding the fact that its last remaining objective is to grant as many European Patents as possible (and as fast as possible), conveniently conflating quality with pace



  7. A Reader's Suggestion: Directions for Techrights

    Guest post by figosdev



  8. Links 20/4/2019: Weblate 3.6 and Pop!_OS 19.04

    Links for the day



  9. The Likes of Chartered Institute of Patent Attorneys (CIPA), Team Campinos and Team UPC Don't Represent Europe But Hurt Europe

    The abject disinterest in patent quality and patent validity (as judged by courts) threatens Europe but not to the detriment of those who are in the 'business' of suing and printing lots of worthless patents



  10. The Linux Foundation Needs to Change Course Before GNU/Linux (as a Free Operating System) is Dead

    The issues associated with the Linux Foundation are not entirely new; but Linux now incorporates so many restrictions and contains so many binary blobs that one begins to wonder what "Linux" even means



  11. Largest Patent Offices Try to Leave Courts in a State of Disarray to Enable the Granting of Fake Patents in the US and Europe

    Like a monarchy that effectively runs all branches of government the management of the EPO is trying to work around the judiciary; the same is increasingly happening (or at least attempted) in the United States



  12. Links 19/4/2019: PyPy 7.1.1, LabPlot 2.6, Kipi Plugins 5.9.1 Released

    Links for the day



  13. Links 18/4/2019: Ubuntu and Derivatives Have Releases, digiKam 6.1.0, OpenSSH 8.0 and LibreOffice 6.2.3

    Links for the day



  14. Freedom is Not a Business and Those Who Make 'Business' by Giving it Away Deserve Naming

    Free software is being parceled and sold to private monopolisers; those who facilitate the process enrich themselves and pose a growing threat to freedom in general — a subject we intend to tackle in the near future



  15. Concluding the Linux Foundation (LF) “Putting the CON in Conference!” (Part 3)

    Conferences constructed or put together based on payments rather than merit pose a risk to the freedom of free software; we conclude our series about events set up by the largest of culprits, which profits from this erosion of freedom



  16. “Mention the War” (of Microsoft Against GNU/Linux)

    The GNU/Linux desktop (or laptops) seems to be languishing or deteriorating, making way for proprietary takeover in the form of Vista 10 and Chrome OS and “web apps” (surveillance); nobody seems too bothered — certainly not the Linux Foundation — by the fact that GNU/Linux itself is being relegated or demoted to a mere “app” on these surveillance platforms (WSL, Croûton and so on)



  17. The European Patent Office Does Not Care About the Law, Today's Management Constantly Attempts to Bypass the Law

    Many EPs (European Patents) are actually "IPs" (invalid patents); the EPO doesn't seem to care and it is again paying for corrupt scholars to toe the party line



  18. The US Supreme Court (SCOTUS) Once Again Pours Cold Water on Patent Maximalists

    Any hopes of a rebound or turnaround have just been shattered because a bizarre attack on the appeal process (misusing tribal immunity) fell on deaf ears and software patents definitely don't interest the highest court, which already deemed them invalid half a decade ago



  19. Links 17/4/2019: Qt 5.12.3 Released, Ola Bini Arrested (Political Stunts)

    Links for the day



  20. Links 16/4/2019: CentOS Turns 15, Qt Creator 4.9.0 Released

    Links for the day



  21. GNU/Linux is Being Eaten Alive by Large Corporations With Their Agenda

    A sort of corporate takeover, or moneyed interests at the expense of our freedom, can be seen as a 'soft coup' whose eventual outcome would involve all or most servers in 'the cloud' (surveillance with patent tax as part of the rental fees) and almost no laptops/desktops which aren't remotely controlled (and limit what's run on them, using something like UEFI 'secure boot')



  22. Reader's Claim That Rules Similar to the Code of Conduct (CoC) Were 'Imposed' on LibrePlanet and the FSF

    Restrictions on speech are said to have been spread and reached some of the most liberal circles, according to a credible veteran who opposes illiberal censorship



  23. Corporate Media Will Never Cover the EPO's Violations of the Law With Respect to Patent Scope

    The greed-driven gold rush for patents has resulted in a large pool of European Patents that have no legitimacy and are nowadays associated with low legal certainty; the media isn't interested in covering such a monumental disaster that poses a threat to the whole of Europe



  24. A Linux Foundation Run by People Who Reject Linux is Like a Children's Charity Whose Management Dislikes Children

    We remain concerned about the lack of commitment that the Linux Foundation has for Linux; much of the Linux Foundation's Board, for example, comes from hostile companies



  25. Links 15/4/2019: Linux 5.1 RC5 and SolydXK Reviewed

    Links for the day



  26. Links 14/4/2019: Blender 2.80 Release Plan and Ducktype 1.0

    Links for the day



  27. 'Poor' (Multi-Millionaire) Novell CEO, Who Colluded With Steve Ballmer Against GNU/Linux, is Trying to Censor Techrights

    Novell’s last CEO, a former IBMer who just like IBM decided to leverage software patents against the competition (threatening loads of companies using "platoons of patent lawyers"), has decided that siccing lawyers at us would be a good idea



  28. Guest Post: The Linux Foundation (LF) is “Putting the CON in Conference!” (Part 2)

    Calls for papers (CfP) and who gets to assess what's presented or what's not presented is a lesser-explored aspect, especially in this age when large corporate sponsors get to indirectly run entire 'community' events



  29. Patent Maximalists Are Enabling Injustices and Frauds

    It's time to come to grips with the simple fact that extreme patent lenience causes society to suffer and is mostly beneficial to bad actors; for the patent profession to maintain a level of credibility and legitimacy it must reject the deplorable, condemnable zealots



  30. Further Decreasing Focus on Software Patents in the United States as They Barely Exist in Valid Form Anymore

    No headway made after almost 4 months of Iancu-led stunts; software patents remain largely dead and buried, so we’re moving on to other topics


CoPilotCo

RSS 64x64RSS Feed: subscribe to the RSS feed for regular updates

Home iconSite Wiki: You can improve this site by helping the extension of the site's content

Home iconSite Home: Background about the site and some key features in the front page

Chat iconIRC Channel: Come and chat with us in real time

CoPilotCo

Recent Posts